<!DOCTYPE html>
<html lang="zh">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Isodeoxyelephantopin Promotes Cell Death in Triple‚ÄêNegative Breast Cancer byBlocking STAT3 Phosphorylation and Enhancing the Effectiveness of Paclitaxel -PMC</title>
  <style>
    body {
      font-family: "Helvetica Neue", "Noto Sans TC", sans-serif;
      max-width: 720px;
      margin: 2em auto;
      padding: 0 1em;
      color: #333;
      line-height: 1.8;
      background: #fff;
    }
    h1, h2, h3 {
      text-align: center;
      color: #222;
    }
    .lang-switcher {
      text-align: center;
      margin-bottom: 2em;
    }
    .lang-btn {
      margin: 0 0.5em;
      padding: 0.4em 1em;
      border: none;
      background-color: #eee;
      border-radius: 4px;
      cursor: pointer;
      font-weight: bold;
    }
    .lang-btn.active {
      background-color: #007acc;
      color: white;
    }
    ul {
      padding-left: 1.2em;
    }
    a {
      color: #007acc;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    img {
      max-width: 100%;
      height: auto;
    }
    .share-block {
      text-align: center;
      margin: 1em 0 2em;
      font-size: 0.95em;
    }
    .share-block a svg {
      width: 24px;
      height: 24px;
      display: inline-block;
      vertical-align: middle;
      margin: 0 0.4em;
      transition: transform 0.2s ease;
      cursor: pointer;
    }
    .share-block a svg:hover {
      transform: scale(1.2);
    }
  </style>

</head>
<body>
  <h1>Isodeoxyelephantopin Promotes Cell Death in Triple‚ÄêNegative Breast Cancer byBlocking STAT3 Phosphorylation and Enhancing the Effectiveness of Paclitaxel -PMC</h1>
  
  <div class="share-block">
    <span>üîó ÂàÜ‰∫´ÈÄôÁØáÊëòË¶ÅÔºö</span>
    <a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fisodeoxyelephantopin-promotes-cell-death-in-triplenegative-breast-cancer-byblocking-stat3-phosphorylation-and-enhancing-the-effectiveness-of-paclitaxel-pmc-summary.html" target="_blank" title="Facebook">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M512 256C512 114.6 397.4 0 256 0S0 114.6 0 256C0 376 82.7 476.8 194.2 504.5V334.2H141.4V256h52.8V222.3c0-87.1 39.4-127.5 125-127.5c16.2 0 44.2 3.2 55.7 6.4V172c-6-.6-16.5-1-29.6-1c-42 0-58.2 15.9-58.2 57.2V256h83.6l-14.4 78.2H287V510.1C413.8 494.8 512 386.9 512 256h0z"/></svg>
    </a>
    <a href="https://x.com/intent/tweet?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fisodeoxyelephantopin-promotes-cell-death-in-triplenegative-breast-cancer-byblocking-stat3-phosphorylation-and-enhancing-the-effectiveness-of-paclitaxel-pmc-summary.html&text=Isodeoxyelephantopin%20Promotes%20Cell%20Death%20in%20Triple%E2%80%90Negative%20Breast%20Cancer%20byBlocking%20STAT3%20Phosphorylation%20and%20Enhancing%20the%20Effectiveness%20of%20Paclitaxel%20-PMC" target="_blank" title="X">
      <svg xmlns="http://www.w3.org/2000/svg" x="0px" y="0px" width="100" height="100" viewBox="0 0 50 50">
<path d="M 11 4 C 7.134 4 4 7.134 4 11 L 4 39 C 4 42.866 7.134 46 11 46 L 39 46 C 42.866 46 46 42.866 46 39 L 46 11 C 46 7.134 42.866 4 39 4 L 11 4 z M 13.085938 13 L 21.023438 13 L 26.660156 21.009766 L 33.5 13 L 36 13 L 27.789062 22.613281 L 37.914062 37 L 29.978516 37 L 23.4375 27.707031 L 15.5 37 L 13 37 L 22.308594 26.103516 L 13.085938 13 z M 16.914062 15 L 31.021484 35 L 34.085938 35 L 19.978516 15 L 16.914062 15 z"></path></svg>
    </a>
    <a href="https://www.threads.net/intent/post?url=https%3A%2F%2Fbreastcancer-tech.github.io%2Fbreast-cancer-1%2Farticles%2Fisodeoxyelephantopin-promotes-cell-death-in-triplenegative-breast-cancer-byblocking-stat3-phosphorylation-and-enhancing-the-effectiveness-of-paclitaxel-pmc-summary.html&text=Isodeoxyelephantopin%20Promotes%20Cell%20Death%20in%20Triple%E2%80%90Negative%20Breast%20Cancer%20byBlocking%20STAT3%20Phosphorylation%20and%20Enhancing%20the%20Effectiveness%20of%20Paclitaxel%20-PMC" target="_blank" title="Threads">
      <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.7.2 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2025 Fonticons, Inc.--><path d="M64 32C28.7 32 0 60.7 0 96V416c0 35.3 28.7 64 64 64H384c35.3 0 64-28.7 64-64V96c0-35.3-28.7-64-64-64H64zM294.2 244.3c19.5 9.3 33.7 23.5 41.2 40.9c10.4 24.3 11.4 63.9-20.2 95.4c-24.2 24.1-53.5 35-95.1 35.3h-.2c-46.8-.3-82.8-16.1-106.9-46.8C91.5 341.8 80.4 303.7 80 256v-.1-.1c.4-47.7 11.5-85.7 33-113.1c24.2-30.7 60.2-46.5 106.9-46.8h.2c46.9 .3 83.3 16 108.2 46.6c12.3 15.1 21.3 33.3 27 54.4l-26.9 7.2c-4.7-17.2-11.9-31.9-21.4-43.6c-19.4-23.9-48.7-36.1-87-36.4c-38 .3-66.8 12.5-85.5 36.2c-17.5 22.3-26.6 54.4-26.9 95.5c.3 41.1 9.4 73.3 26.9 95.5c18.7 23.8 47.4 36 85.5 36.2c34.3-.3 56.9-8.4 75.8-27.3c21.5-21.5 21.1-47.9 14.2-64c-4-9.4-11.4-17.3-21.3-23.3c-2.4 18-7.9 32.2-16.5 43.2c-11.4 14.5-27.7 22.4-48.4 23.5c-15.7 .9-30.8-2.9-42.6-10.7c-13.9-9.2-22-23.2-22.9-39.5c-1.7-32.2 23.8-55.3 63.5-57.6c14.1-.8 27.3-.2 39.5 1.9c-1.6-9.9-4.9-17.7-9.8-23.4c-6.7-7.8-17.1-11.8-30.8-11.9h-.4c-11 0-26 3.1-35.6 17.6l-23-15.8c12.8-19.4 33.6-30.1 58.5-30.1h.6c41.8 .3 66.6 26.3 69.1 71.8c1.4 .6 2.8 1.2 4.2 1.9l.1 .5zm-71.8 67.5c17-.9 36.4-7.6 39.7-48.8c-8.8-1.9-18.6-2.9-29-2.9c-3.2 0-6.4 .1-9.6 .3c-28.6 1.6-38.1 15.5-37.4 27.9c.9 16.7 19 24.5 36.4 23.6l-.1-.1z"/></svg>
    </a>
  </div>

  <div style="text-align: center;"><img src="https://i.imgur.com/H4JFuyI.png" alt="News Cover Image" style="max-width: 100%; height: auto; border-radius: 12px; margin-bottom: 1.5em;"></div>
  <div class="lang-switcher">
    <button class="lang-btn active" data-lang="zh">‰∏≠Êñá</button><button class="lang-btn " data-lang="en">English</button><button class="lang-btn " data-lang="jp">Êó•Êú¨Ë™û</button>
  </div>
  
  <div class="ads-block" style="margin: 2.5em 0; position: relative; text-align: center;">
    <a href="https://cancerfree.io/" target="_blank" style="display: inline-block; position: relative;">
      <img src="https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQI9CDgh7JwzUGH4QTfT5Su2MGI3gUURdf3Tw&s" alt="Advertisement" style="width: 100%; border-radius: 12px; box-shadow: 0 2px 6px rgba(0,0,0,0.1);">
      <div style="
        position: absolute;
        top: 8px;
        right: 8px;
        background: rgba(0, 0, 0, 0.6);
        color: white;
        font-size: 0.75rem;
        padding: 2px 6px;
        border-radius: 4px;
        font-weight: bold;
        letter-spacing: 0.5px;
      ">
        Âª£Âëä
      </div>
    </a>
  </div>
  
  <div class="lang-content" data-lang="zh" style="">Okay, here's a breakdown of the provided text, organized to be more easily digestible.  I'm focusing on extracting key information and structuring it.

**Overall Theme:** This is a collection of citations and summaries related to research on **STAT3 (Signal Transducer and Activator of Transcription 3)**, particularly in the context of cancer treatment and immune evasion.  The focus is on how STAT3 signaling is targeted to improve cancer therapies.

**I. STAT3: A Brief Overview**

*   **What it is:** STAT3 is a transcription factor involved in cell growth, survival, and immune responses. It's often dysregulated in cancer.
*   **Why it's a Target:**  Because of its role in cancer progression, STAT3 is a promising target for therapeutic intervention.

**II. Research Citations & Summaries (Organized by Key Areas)**

I'm grouping the citations by the main themes they address.  Each entry includes the citation number, authors, year, journal, and a brief summary.

**A. STAT3 Inhibition & Cancer Treatment**

*   **1. Celastrol & Cisplatin Nephrotoxicity (Yu et al., 2018):** Celastrol inhibits NFkappaB and improves mitochondrial function, ameliorating cisplatin-induced kidney damage.
*   **2. Stattic & FGFR Inhibition (Zhong et al., 2024):** Stattic (a STAT3 inhibitor) exhibits a synergistic effect when combined with Erdafitinib (an FGFR inhibitor) in lung squamous cell carcinoma.
*   **3. JAK/STAT3 Inhibition in AML (Zuo et al., 2024):**  Targeted nanoliposomes inhibit JAK/STAT3 expression, enhancing chemotherapy for acute myeloid leukemia (AML).

**B. STAT3 & Immune Evasion**

*   **4. STAT3 in Tumor Immune Evasion (Zhang et al., 2022):**  Explores the role of STAT3 signaling in how tumors evade the immune system.
*   **5. Targeting STAT3 in Cancer Immunotherapy (Zou et al., 2020):**  A review of strategies to target STAT3 to enhance cancer immunotherapy.

**C. STAT3 & Specific Cancer Types**

*   **6. Triple-Negative Breast Cancer (TNBC) (Zhu et al., 2023):**  Reviews recent advances in targeted therapies for TNBC, likely including strategies to target STAT3.
*   **7. Colorectal Cancer (Wu et al., 2023):** Nuclear translocation of Thioredoxin1 promotes colorectal cancer development via modulation of the IL6/STAT3 signaling axis.

**D. STAT3 & Signaling Pathways**

*   **8. STAT3 & NFkappaB (Yu et al., 2018):**  Celastrol inhibits NFkappaB, a key signaling pathway often linked to STAT3.
*   **9. STAT3 & IL6 (Wu et al., 2023):**  STAT3 is part of the IL6/STAT3 signaling axis, a critical pathway in colorectal cancer.

**III. Associated Data**

*   **Data Availability:** The data presented in the study are available in the article.

**Key Takeaways:**

*   **STAT3 is a validated target:**  Numerous studies demonstrate the potential of targeting STAT3 in various cancers.
*   **Combination therapies are promising:** Combining STAT3 inhibitors with other therapies (like FGFR inhibitors or chemotherapy) often shows enhanced efficacy.
*   **STAT3 impacts multiple pathways:** STAT3 is involved in complex signaling networks, making it a central node for therapeutic intervention.
*   **Research is ongoing:**  The field is actively exploring new strategies to effectively target STAT3 and overcome resistance mechanisms.

**To help me refine this further, could you tell me:**

*   What is the purpose of this collection of citations? (e.g., literature review, grant proposal, etc.)
*   Are there any specific aspects of STAT3 research you're most interested in?</div><div class="lang-content" data-lang="en" style="display: none;">Okay, here's a breakdown of the provided text, focusing on extracting key information and organizing it.  I'm focusing on the themes of cancer treatment, particularly focusing on STAT3 and related pathways.

**I. Overall Theme:**

The text is a collection of abstracts and summaries from research articles focusing on cancer treatment strategies. A significant portion of the research revolves around targeting the STAT3 signaling pathway, often in combination with other therapies.  The research spans various cancer types, including colorectal, lung, leukemia, and triple-negative breast cancer.

**II. Key Pathways & Targets:**

*   **STAT3 Signaling Pathway:** This is the central focus.  Many articles investigate inhibiting STAT3 to impact cancer development and treatment response.
*   **NF-Œ∫B Pathway:** Frequently mentioned in conjunction with STAT3.  Inhibition of NF-Œ∫B is often a strategy to impact cancer progression.
*   **JAK-STAT3 Pathway:**  A specific combination targeted in some research.
*   **IL-6/STAT3 Signaling Axis:**  A specific interaction being modulated.
*   **FGFRs (Fibroblast Growth Factor Receptors):** Targeted in combination with STAT3 inhibitors.
*   **JAK (Janus Kinase):** Targeted in combination with STAT3 inhibitors.

**III. Cancer Types Investigated:**

*   **Colorectal Cancer:**  Research focuses on nuclear translocation of Thioredoxin1 and its impact on the IL6/STAT3 axis.
*   **Lung Squamous Cell Carcinoma:**  STAT3 inhibitor (Stattic) is tested in combination with an FGFR inhibitor (Erdafitinib).
*   **Acute Myeloid Leukemia (AML):**  Targeted nanoliposomes are used to inhibit JAK-STAT3 expression.
*   **Triple-Negative Breast Cancer (TNBC):**  Research focuses on targeted strategies and combination therapies.
*   **General Cancer:** Many articles discuss STAT3 inhibition as a broader strategy.

**IV. Therapeutic Approaches & Combinations:**

*   **STAT3 Inhibitors:**  Directly targeting STAT3. (e.g., Stattic)
*   **FGFR Inhibitors:**  Combined with STAT3 inhibitors.
*   **JAK Inhibitors:** Combined with STAT3 inhibitors.
*   **Nanoliposomes:** Used for targeted drug delivery to inhibit JAK-STAT3.
*   **Combination Therapies:**  Frequently explored to enhance efficacy and overcome resistance.
*   **Targeted Therapies:**  A general approach, often involving specific inhibitors.

**V. Specific Compounds/Agents Mentioned:**

*   **Celastrol:** Ameliorates cisplatin nephrotoxicity by inhibiting NF-Œ∫B.
*   **Stattic:** A STAT3 inhibitor.
*   **Erdafitinib:** An FGFR inhibitor.
*   **Thioredoxin-1:**  Its nuclear translocation is linked to cancer development.

**VI. Data Availability:**

*   The data presented in the study are available in the article.

**VII. Summary Table (Concise Overview):**

| **Cancer Type** | **Target Pathway(s)** | **Therapeutic Approach** | **Key Findings/Focus** |
|---|---|---|---|
| Colorectal | IL6/STAT3 | Inhibition of Thioredoxin-1 | Nuclear translocation promotes cancer development |
| Lung Squamous Cell | STAT3, FGFR | STAT3 inhibitor + FGFR inhibitor | Synergistic effect |
| AML | JAK-STAT3 | Targeted nanoliposomes | Inhibits JAK-STAT3 expression |
| TNBC | STAT3, NF-Œ∫B | Targeted therapies, combination therapies |  Improving treatment response |
| General | STAT3, NF-Œ∫B | Various inhibitors, combination therapies | Broad strategy for cancer treatment |

**Important Notes:**

*   This is a summary based solely on the provided text.  The full context of each research article would provide more detail.
*   The text highlights the complexity of cancer treatment and the importance of targeting multiple pathways.
*   Combination therapies are a recurring theme, suggesting that a multi-faceted approach is often necessary.</div><div class="lang-content" data-lang="jp" style="display: none;">Okay, here's a breakdown of the provided text, focusing on extracting key information and organizing it.  I'm aiming to provide a structured summary of the research themes and findings presented in the list of publications.

**Overall Theme:** The publications focus heavily on the **STAT3 signaling pathway** and its role in cancer development, immune evasion, and therapeutic interventions.  A significant portion also addresses **Triple-Negative Breast Cancer (TNBC)** and strategies for targeting it.  Other pathways like NF-Œ∫B, JAK/STAT, and FGFR are also frequently mentioned in conjunction with STAT3.

**I. STAT3 Signaling & Cancer (General)**

*   **Role in Development:** STAT3 is implicated in cancer development, immune evasion, and therapeutic resistance. (Publications 47, 43, 1)
*   **Therapeutic Targeting:**  Numerous studies explore strategies to inhibit STAT3, either alone or in combination with other therapies. (Publications 47, 1, 45, 46, 44, 40)
*   **Interaction with Other Pathways:** STAT3 often interacts with other signaling pathways, such as NF-Œ∫B, JAK/STAT, and FGFR, influencing cancer progression. (Publications 2, 43, 44, 40)
*   **Specific Mechanisms:**
    *   Nuclear translocation of Thioredoxin-1 modulates the IL6-STAT3 signaling axis. (Publication 41)
    *   STAT3 inhibition can enhance chemotherapy. (Publication 16)

**II. STAT3 & Triple-Negative Breast Cancer (TNBC)**

*   **Significant Focus:** TNBC is a major area of investigation, with multiple publications specifically addressing its treatment. (Publications 45, 40, 16, 17)
*   **Targeted Strategies:** Research focuses on developing targeted therapies for TNBC, often involving STAT3 inhibition. (Publications 45, 40, 16, 17)
*   **Combination Therapies:** Combining STAT3 inhibitors with other therapies (e.g., FGFR inhibitors) shows promise in TNBC. (Publication 44)

**III. Specific Publications & Key Findings (Summarized)**

Here's a brief summary of each publication, highlighting the core findings:

1.  **Zou et al. (2020):** Targeting STAT3 in Cancer Immunotherapy - Reviews the role of STAT3 in immune evasion and explores therapeutic strategies.
2.  **Wu et al. (2023):** Nuclear Translocation of Thioredoxin-1 -  Identifies a mechanism where Thioredoxin-1 promotes colorectal cancer through modulation of the IL6-STAT3 signaling axis.
3.  **Zhang et al. (2022):** Signal Transducer and Activator of Transcription 3 Signaling - Examines the role of STAT3 in tumor immune evasion.
4.  **Zhong et al. (2024):** STAT3 Inhibitor Stattic - Demonstrates synergistic effects of Stattic (a STAT3 inhibitor) with Erdafitinib (an FGFR inhibitor) in FGFR1-positive lung cancer.
5.  **Zhu et al. (2023):** Recent Advances in Targeted Strategies - Reviews targeted therapies for TNBC, including STAT3 inhibition.
6.  **Yu et al. (2018):** Celastrol Ameliorates Cisplatin Nephrotoxicity - Shows that Celastrol inhibits NF-Œ∫B and improves mitochondrial function, ameliorating cisplatin nephrotoxicity.
7.  **Zuo et al. (2024):** Inhibition of JAKSTAT3 Expression - Describes a nanoliposome delivery system to inhibit JAKSTAT3 expression and enhance chemotherapy.
8.  **Wong et al. (2022):** STAT Family in Breast Cancer - Reviews the role of the STAT family in breast cancer pathogenesis and therapeutic opportunities.
9.  **Kuca et al. (2022):** STAT3 Signaling in Tumor Immune Evasion - Explores the role of STAT3 in tumor immune evasion.
10. **Tong et al. (2020):** Targeting STAT3 in Cancer Immunotherapy - Reviews the role of STAT3 in immune evasion and explores therapeutic strategies.

**IV.  Key Pathways & Molecules Mentioned**

*   **STAT3:** Central focus of the research.
*   **NF-Œ∫B:** Frequently interacts with STAT3.
*   **JAK/STAT:**  Related pathway often investigated alongside STAT3.
*   **FGFR:**  Targeted in combination with STAT3 inhibitors.
*   **Thioredoxin-1:**  Mechanism for promoting cancer.
*   **IL6:**  Signaling molecule involved in STAT3 activation.
*   **Celastrol:** Compound with therapeutic potential.
*   **Erdafitinib:** FGFR inhibitor.
*   **Stattic:** STAT3 inhibitor.

**V.  Overall Conclusion**

The research highlights the critical role of the STAT3 signaling pathway in cancer development and progression. Targeting STAT3, particularly in combination with other therapies, holds significant promise for treating various cancers, especially TNBC.  Further research is needed to fully elucidate the mechanisms involved and to develop more effective and targeted therapies.</div>
  <p style="text-align:center; margin-top: 2em;">
    <a href="./isodeoxyelephantopin-promotes-cell-death-in-triplenegative-breast-cancer-byblocking-stat3-phosphorylation-and-enhancing-the-effectiveness-of-paclitaxel-pmc-seo.html">üëâ Êü•ÁúãÂéüÊñá / Full Article</a>
  </p>
  <script>
    document.querySelectorAll('.lang-btn').forEach(btn => {
      btn.addEventListener('click', () => {
        const lang = btn.dataset.lang;
        document.querySelectorAll('.lang-btn').forEach(b => b.classList.remove('active'));
        btn.classList.add('active');
        document.querySelectorAll('.lang-content').forEach(div => {
          div.style.display = div.dataset.lang === lang ? '' : 'none';
        });
      });
    });
  </script>
</body>
</html>